Innate Pharma S.A.는 프랑스 및 전 세계 암 환자를 위한 면역치료제를 개발하는 생명공학 기업입니다. 이 회사의 제품으로는 다음이 있습니다: 피부 T세포 림프종 및 말초 T세포 림프종 치료를 위한 임상 2상 시험 중인 항-KIR3DL2 항체인 Lacutamab (IPH4102); 넥틴-4를 표적으로 하는 엑사테칸 접합 신규 차별화 토포이소머라제 I 억제제 ADC인 IPH4502; 그리고 T세포와 NK세포를 표적으로 하는 이중 체크포인트 억제제인 Monalizumab. 또한, 이 회
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
